ARTICLE | Clinical News
Regeneron begins Phase II
March 28, 2000 8:00 AM UTC
REGN began a Phase II trial of its Axokine second generation ciliary neurotrophic factor ( CNTF) to treat obesity and associated complications such as Type II diabetes. The double-blind, dose-ranging ...